Mayo Clinic Q&A: FDA Sets Stricter Standards for COVID-19 Vaccine Development

Everyone
  • 1 video | 18m 29s
Likes 19 Likes 19
In an effort to reassure the public about the safety and effectiveness of a vaccine, the Food and Drug Administration has set stricter standards for COVID-19 vaccine development. These standards include following phase 3 clinical trial participants for at least two months, and having at least five severe COVID-19 cases in the placebo group. The agency's requirements are designed to ensure that there is adequate safety data on any vaccine before it is authorized for emergency use. (Published 10/14/2020)

IN THIS COURSE

  • 18m 29s
    On the Mayo Clinic Q&A podcast, Dr. Gregory Poland, an infectious disease expert and head of Mayo Clinic's Vaccine Research Group, discusses vaccine development standards and shares concerns about the second wave of COVID-19 infections. (Published 10/14/2020) FREE ACCESS

YOU MIGHT ALSO LIKE

Course Mayo Clinic Q&A: Don't Let Down Your Guard During the COVID-19 Pandemic
Likes 21 Likes 21  
Course Mayo Clinic Q&A: A race between vaccines, the virus and variants
Likes 28 Likes 28  
Course Mayo Clinic COVID-19 Live Webinar Series - January 20, 2021: Supply Chain Considerations for Delivering the COVID-19 Vaccine
Likes 22 Likes 22